Medicinal Cannabis Industry Australia (MCIA) is pleased to partner with FreshLeaf for the third year running in the release of FreshLeaf’s latest comprehensive analysis of medicinal cannabis products, pricing and patients.Continue reading “Industry report shows strong growth in Australian patient access to medicinal cannabis”
Medicinal Cannabis Industry Australia (MCIA) welcomes the Therapeutic Goods Administration (TGA) announcement of its final decision regarding down-scheduling of low-dose CBD, including the significant change to the maximum dose which has been increased to 150mg/day.
MCIA had recommended changes to the interim decision, and in particular the low daily dose, to ensure that there is an effective pathway for S3 CBD products. A report commissioned by MCIA supported a higher dose based on safety and efficacy, and hence, ability to meet the evidentiary requirements for the proposed registration pathway. MCIA is pleased that TGA’s further consideration of this information, along with other public submissions, and the advice of the Joint Committee of the Advisory Committees for Medicines Scheduling and Chemicals Scheduling at its November 2020 meeting, has led to a lifting of the daily dose.Continue reading “MCIA welcomes decision for down scheduled CBD with increased maximum dose of 150mg/day”
Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome Dr Richard Di Natale as the inaugural chair of the newly established Medicinal Cannabis Health Advisory Council.
“Richard has been a great champion of medicinal cannabis access for patients and will provide invaluable guidance as chair of this unique and important Advisory Council” said Peter Crock Chair of MCIA.Continue reading “Medicinal cannabis champion to chair new Advisory Council”
In responding to the Therapeutic Goods Administration’s (TGA) interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines at appropriate dosage levels, Medicinal Cannabis Industry Australia (MCIA) has recommended further change to the proposed scheduling to ensure that there is an effective pathway for S3 CBD products.
Medicinal cannabis has an important role to play in improving health outcomes. MCIA supports down- scheduling of CBD to S3, which has the potential to provide patients with improved access to a safe low dose cannabis product for medical use.Continue reading “MCIA pursues better patient access for down scheduled CBD”
Medicinal Cannabis Industry Australia has welcomed the interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines.
In the interim decision released today, the Therapeutic Goods Administration (TGA) has supported the down scheduling of CBD to allow greater patient access through enabling registered low-dose CBD products to be available as a Schedule 3 medicine.Continue reading “MCIA welcomes TGA interim decision to down schedule CBD”
Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome the establishment of a Parliamentary Friends of Medicinal Cannabis Group in the Federal Parliament.
The group will provide a non-partisan forum for Members and Senators to meet with representatives of the Australian medicinal cannabis industry, medical experts and patient advocates to raise awareness of the applications of medicinal cannabis to Parliamentarians and within the broader community.Continue reading “MCIA welcomes new Parliamentary Friends of Medicinal Cannabis Group”
MCIA and MCC are pleased to announce that they have entered a collaboration arrangement to create a unified voice for the Australian medicinal cannabis industry.
The Australian medicinal cannabis industry has an important role to play in improving health outcomes for Australian patients. Australia is well placed to lead the world with quality medicinal cannabis, deliver next generation patient well-being, and develop a new export industry.Continue reading “Medicinal Cannabis Industry Australia (MCIA) and Medical Cannabis Council (MCC) collaborate to form a unified voice for the Australian medicinal cannabis industry”
Medicinal Cannabis Industry Australia (MCIA) welcomed the report from The Senate Community Affairs References Committee into Current barriers to patient access to medicinal cannabis in Australia as a key step in assisting patients who are seeking easier and more affordable access to what is a prescription medicine.Continue reading “MCIA welcomes improved patient access to medicinal cannabis”
Early bird tickets on-sale now.
Formed in 2019, Medicinal Cannabis Industry Australia (MCIA) is the peak industry organisation for Australia’s licensed medicinal cannabis industry, with a focus on building an industry that enhances wellbeing through facilitating access to quality Australian medicinal cannabis products for Australian and global patients.Continue reading “An Australian Medicinal Cannabis Conference that will Change the Future.”
The Medicinal Cannabis Industry Australia, (MCIA) is launching the inaugural ACannabis Conference to help define and shape the future of the Australian Medicinal Cannabis industry.
The event will draw together all facet of the industries ecosystem to connect, engage and build a framework to support patients’ well-being, enable best practice, and strengthen growth for the industry.Continue reading “The Future of Medicinal Cannabis Conference Melbourne March 3-4 2020”